Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus DYANAVEL XR 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus DYANAVEL XR 10.
ADDERALL 20 vs DYANAVEL XR 10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Dyanavel XR is a central nervous system stimulant that increases extracellular levels of dopamine and norepinephrine by inhibiting their reuptake and enhancing their release from presynaptic neurons.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
Recommended starting dose for adults is 10 mg orally once daily in the morning. May increase in increments of 5-10 mg at weekly intervals based on tolerability and response. Maximum recommended dose is 60 mg/day.
None Documented
None Documented
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
12 hours (amphetamine); clinical context: extended-release profile allows once-daily dosing
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Renal (80-90% as unchanged drug); fecal (minor, 1-5%)
Category C
Category C
CNS Stimulant
CNS Stimulant